NeoMatrix Therapeutics, Inc. (NMT) was founded by Richard A. Clark, M.D., Professor of Dermatology, Biomedical Engineering, and Medicine at Stony Brook University.

​

After years of investigating why wounds fail to heal, Dr. Clark and Dr. Lin discovered a cell-survival peptide in the extracellular matrix (ECM) protein fibronectin (FN) that is absent in nonhealing wounds and burns.  This peptide, called NMT-cP12, promotes tissue cell survival and growth under harsh culture conditions that mimic unfavorable wound conditions.  Dr. Clark also found that NMT-cP12 limited burn injury progression, shortened healing time and decreased scarring in a porcine burn model burn. 

​

In 2007, the US Army began funding the development of NMT-cP12 and has supported NMT’s continued development of this compound and the Company’s follow-on compound NMT-cNP8.

 

NMT is headquartered in the Long Island High Tech Incubator on the campus of Stony Brook University.